Literature DB >> 23666741

Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.

Massimo Santoro1, Marcella Masciullo, Davide Bonvissuto, Maria Laura Ester Bianchi, Fabrizio Michetti, Gabriella Silvestri.   

Abstract

INSR, one of those genes aberrantly expressed in myotonic dystrophy type 1 (DM1) and type 2 (DM2) due to a toxic RNA effect, encodes for the insulin receptor (IR). Its expression is regulated by alternative splicing generating two isoforms: IR-A, which predominates in embryonic tissue, and IR-B, which is highly expressed in adult, insulin-responsive tissues (skeletal muscle, liver, and adipose tissue). The aberrant INSR expression detected in DM1 and DM2 muscles tissues, characterized by a relative increase of IR-A versus IR-B, was pathogenically related to the insulin resistance occurring in DM patients. To assess if differences in the aberrant splicing of INSR could underlie the distinct fiber type involvement observed in DM1 and DM2 muscle tissues, we have used laser capture microdissection (LCM) and RT-PCR, comparing the alternative splicing of INSR in type I and type II muscle fibers isolated from muscle biopsies of DM1, DM2 patients and controls. In the controls, the relative amounts of IR-A and IR-B showed no obvious differences between type I and type II fibers, as in the whole muscle tissue. In DM1 and DM2 patients, both fiber types showed a similar, relative increase of IR-A versus IR-B, as also evident in the whole muscle tissue. Our data suggest that the distinct fiber type involvement in DM1 and DM2 muscle tissues would not be related to qualitative differences in the expression of INSR. LCM can represent a powerful tool to give a better understanding of the pathogenesis of myotonic dystrophies, as well as other myopathies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666741     DOI: 10.1007/s11010-013-1681-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

1.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Defective satellite cells in congenital myotonic dystrophy.

Authors:  D Furling; L Coiffier; V Mouly; J P Barbet; J L St Guily; K Taneja; G Gourdon; C Junien; G S Butler-Browne
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

3.  Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.

Authors:  R S Savkur; A V Philips; T A Cooper
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

4.  Alternative splicing dysregulation secondary to skeletal muscle regeneration.

Authors:  James P Orengo; Amanda J Ward; Thomas A Cooper
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

5.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

Review 6.  Signaling in muscle atrophy and hypertrophy.

Authors:  Marco Sandri
Journal:  Physiology (Bethesda)       Date:  2008-06

7.  Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis.

Authors:  F Fend; M R Emmert-Buck; R Chuaqui; K Cole; J Lee; L A Liotta; M Raffeld
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

8.  RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance.

Authors:  A Morrone; E Pegoraro; C Angelini; E Zammarchi; G Marconi; E P Hoffman
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

9.  Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2.

Authors:  Valerio Pisani; Maria Beatrice Panico; Chiara Terracciano; Emanuela Bonifazi; Giovanni Meola; Giuseppe Novelli; Giorgio Bernardi; Corrado Angelini; Roberto Massa
Journal:  Muscle Nerve       Date:  2008-11       Impact factor: 3.217

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  23 in total

Review 1.  Trends in insulin resistance: insights into mechanisms and therapeutic strategy.

Authors:  Mengwei Li; Xiaowei Chi; Ying Wang; Sarra Setrerrahmane; Wenwei Xie; Hanmei Xu
Journal:  Signal Transduct Target Ther       Date:  2022-07-06

Review 2.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

3.  Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.

Authors:  Maria Laura Ester Bianchi; Emanuele Leoncini; Marcella Masciullo; Anna Modoni; Shahinaz M Gadalla; Roberto Massa; Emanuele Rastelli; Chiara Terracciano; Giovanni Antonini; Elisabetta Bucci; Antonio Petrucci; Sandro Costanzi; Massimo Santoro; Stefania Boccia; Gabriella Silvestri
Journal:  J Neurol       Date:  2016-01-06       Impact factor: 4.849

4.  Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats.

Authors:  Wenjing Zhang; Yang Wang; Shuyun Dong; Rajarshi Choudhury; Yongfeng Jin; Zefeng Wang
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

5.  Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

Authors:  Lydia Sharp; Diana C Cox; Thomas A Cooper
Journal:  Muscle Nerve       Date:  2019-10-23       Impact factor: 3.217

Review 6.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

7.  Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2.

Authors:  Alessandra Perfetti; Simona Greco; Pasquale Fasanaro; Enrico Bugiardini; Rosanna Cardani; Jose M Garcia-Manteiga; Jose M Garcia Manteiga; Michela Riba; Davide Cittaro; Elia Stupka; Giovanni Meola; Fabio Martelli
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

Review 8.  Influence of Age on Skeletal Muscle Hypertrophy and Atrophy Signaling: Established Paradigms and Unexpected Links.

Authors:  Eun-Joo Lee; Ronald L Neppl
Journal:  Genes (Basel)       Date:  2021-05-03       Impact factor: 4.096

9.  Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Authors:  Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.316

Review 10.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.